Canadian Cancer Trials Group Bulletins

Trial Management Group


Trials Closed to Accrual

The following three trials were recently closed to accrual:

Canadian Cancer Trials Group PRC.2 (CALGB90202) -- A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Early versus Standard Zoledronic Acid to Prevent Skeletal Related Events in Men with Prostate Cancer Metastatic to Bone -- was closed to accrual on April 2, 2012.

Canadian Cancer Trials Group IND.200 -- A Phase II Study of SB939 in Patients with Translocation-Associated Recurrent/Metastatic Sarcomas -- was closed to accrual on January 25, 2012.

Canadian Cancer Trials Group IND.203 -- A Phase I Study of SB939 in Pediatric Patients with Refractory Solid Tumours and Leukemia -- was closed to accrual on January 25, 2012.

Thanks to all participating centres, staff and patients for their participation on these trials.